Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 42Rectal Neoplasms 31Colorectal Neoplasms 31Pancreatic Neoplasms 30Neoplasms 26Stomach Neoplasms 20Neoplasm Metastasis 17Colonic Neoplasms 13Unspecified Adult Solid Tumor, Protocol Specific 12Esophageal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Solid Tumor 7Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Liver Neoplasms 4Carcinoma, Hepatocellular 4Bile Duct Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Appendiceal Neoplasms 3Anus Neoplasms 3Adenocarcinoma 3Vaginal Neoplasms 2Uterine Cervical Neoplasms 2

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × HER-2 Gene Amplification × Capecitabine × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡